Melatonin PR

Phase 2Small molecule

SSeoul National University Hospital

Melatonin PR is one of 8 small molecule programs targeting REM sleep behavior disorder. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

REM Sleep Behavior DisorderActive, not recruiting

REM Sleep Behavior DisorderPhase 2

Active, not recruiting

Competition

Competitive Landscape

9 competitors in REM Sleep Behavior Disorder

#DrugCompanyPhaseTrials

Xyrem

Jazz Pharmaceuticals

Approved

1 2

Rozerem

Takeda

Approved

1 3

Hetlioz

VVanda Pharmaceuticals

Approved

—4

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Phase 2

2 5

Humira

CCelltrion

Phase 2

1 6

Nelotanserin

AAxovant Sciences Ltd.

Phase 2

2 7

Circadin

NNeurim Pharmaceuticals Ltd.

Preclinical

—8

Melatonin PR

SSeoul National University Hospital

Phase 2

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

REM sleep behavior disorder1 trial

Efficacy and Safety of Melatonin PR and Clonazepam in Patients With REM Sleep Behavior Disorder in Parkinson Disease

Unknown status·SSeoul National University Hospital·Phase 2·NCT02789592·30 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Melatonin PR. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Melatonin PR compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Melatonin PR. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Seoul National University Hospital company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: SSeoul National University Hospital

Melatonin PR

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

REM sleep behavior disorder1 trial

References

Drug Info

Quick Facts

Related News